1 insider bought €455k of shares over the last 90 days, the latest by 王敏文, filed 30 Jul 2026.
Xianhe Co.,Ltd. is a listed company. Its directors and officers file their transactions with SSE / SZSE (CSRC). From 26 October 2025 to 26 October 2026, the disclosure feed for Xianhe Co.,Ltd. logged 7 filings by 2 insiders.
No insider sold shares on the market over the period. Instead, the filings list 7 purchases totalling €4.3M, made by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €2.3M, bought by 王敏良 and made public on 24 July 2026. Among those who bought: 2 board members.
The data flag 6 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 30 July 2026, 88 days ago. Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. The shorter that gap, the sooner other investors can see what insiders have done.
For context, the typical company on the same exchange (median of 515 companies) published 2 filings over the same period, against 7 filings here. Over the whole record (from 2026), the tally stands at 7 purchases and no sales.
Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
7 of 7 declarations
Xianhe Co., Ltd. is a company listed on the Shanghai Stock Exchange, specializing in the production and sale of health-related products. It focuses on innovation and quality to meet market demands.